BACKGROUND NOTE: Each year WHO and UNICEF jointly review reports submitted by Member States regarding national immunization coverage, finalized survey reports as well as data from the published and grey literature. Based on these data, with due consideration to potential biases and the views of local experts, WHO and UNICEF attempt to distinguish between situations where the available empirical data accurately reflect immunization system performance and those where the data are likely to be compromised and present a misleading view of immunization coverage while jointly estimating the most likely coverage levels for each country.

WHO and UNICEF estimates are country-specific; that is to say, each country’s data are reviewed individually, and data are not borrowed from other countries in the absence of data. Estimates are not based on ad hoc adjustments to reported data; in some instances empirical data are available from a single source, usually the nationally reported coverage data. In cases where no data are available for a given country/vaccine/year combination, data are considered from earlier and later years and interpolated to estimate coverage for the missing year(s). In cases where data sources are mixed and show large variation, an attempt is made to identify the most likely estimate with consideration of the possible biases in available data. For methods see:

*Brown et al. 2013. An introduction to the grade of confidence used to characterize uncertainty around immunization coverage: a computational logic approach.

DATA SOURCES.

ADMINISTRATIVE coverage: Reported by national authorities and based on aggregated administrative reports from health service providers on the number of vaccinations administered during a given period (numerator data) and reported target population data (denominator data). May be biased by inaccurate numerator and/or denominator data.

OFFICIAL coverage: Estimated coverage reported by national authorities that reflects their assessment of the most likely coverage based on any combination of administrative coverage, survey-based estimates or other data sources or adjustments. Approaches to determine OFFICIAL coverage may differ across countries.

SURVEY coverage: Based on estimated coverage from population-based household surveys among children aged 12-23 months or 24-35 months following a review of survey methods and results. Information is based on the combination of vaccination history from documented evidence or caregiver recall. Survey results are considered for the appropriate birth cohort based on the period of data collection.

ABBREVIATIONS

BCG: percentage of births who received one dose of Bacillus Calmette Guerin vaccine.
DTP1 / DTP3: percentage of surviving infants who received the 1st / 3rd dose, respectively, of diphtheria and tetanus toxoid with pertussis containing vaccine.
Pol3: percentage of surviving infants who received the 3rd dose of polio containing vaccine. May be either oral or inactivated polio vaccine.
IPV1: percentage of surviving infants who received at least one dose of inactivated polio vaccine. In countries utilizing an immunization schedule recommending either (i) a primary series of three doses of oral polio vaccine (OPV) plus at least one dose of IPV where OPV is included in routine immunization and/or campaign or (ii) a sequential schedule of IPV followed by OPV, WHO and UNICEF estimates for IPV1 reflect coverage with at least one routine dose of IPV among infants <1 year of age among countries. For countries utilizing IPV containing vaccine use only, i.e., no recommended dose of OPV, the WHO and UNICEF estimate for IPV1 corresponds to coverage for the 1st dose of IPV.

Production of IPV coverage estimates, which begins in 2015, results in no change of the estimated coverage levels for the 3rd dose of polio (Pol3). For countries recommending routine immunization with a primary series of three doses of IPV alone, WHO and UNICEF estimated Pol3 coverage is equivalent to estimated coverage with three doses of IPV. For countries with a sequential schedule, estimated Pol3 coverage is based on that for the 3rd dose of polio vaccine regardless of vaccine type.

MCV1: percentage of surviving infants who received the 1st dose of measles containing vaccine. In countries where the national schedule recommends the 1st dose of MCV at 12 months or later based on the epidemiology of disease in the country, coverage estimates reflect the percentage of children who received the 1st dose of MCV as recommended.

MCV2: percentage of children who received the 2nd dose of measles containing vaccine according to the nationally recommended schedule.

RCV1: percentage of surviving infants who received the 1st dose of rubella containing vaccine. Coverage estimates are based on WHO and UNICEF estimates of coverage for the dose of measles containing vaccine that corresponds to the first measles-rubella combination vaccine. Nationally reported coverage of RCV is not taken into consideration nor are the data represented in the accompanying graph and data table.

HepBB: percentage of births which received a dose of hepatitis B vaccine within 24 hours of delivery. Estimates of hepatitis B birth dose coverage are produced only for countries with a universal birth dose policy. Estimates are not produced for countries that recommend a birth dose to infants born to HepB virus-infected mothers only or where there is insufficient information to determine whether vaccination is within 24 hours of birth.

HepB3: percentage of surviving infants who received the 3rd dose of hepatitis B containing vaccine following the birth dose.

Hib3: percentage of surviving infants who received the 3rd dose of Haemophilus influenzae type b containing vaccine.

RotaC: percentage of surviving infants who received the final recommended dose of rotavirus vaccine, which can be either the 2nd or the 3rd dose depending on the vaccine.

PcV3: percentage of surviving infants who received the 3rd dose of pneumococcal conjugate vaccine. In countries where the national schedule recommends two doses during infancy and a booster dose at 12 months or later based on the epidemiology of disease in the country, coverage estimates may reflect the percentage of surviving infants who received two doses of PcV prior to the 1st birthday.

YFV: percentage of surviving infants who received one dose of yellow fever vaccine in countries where YFV is part of the national immunization schedule for children or is recommended in at risk areas; coverage estimates are annualized for the entire cohort of surviving infants.

Disclaimer: All reasonable precautions have been taken by the World Health Organization and United Nations Children’s Fund to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization or United Nations Children’s Fund be liable for damages arising from its use.
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data \([R+]\), coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division \([D+]\), and at least one supporting survey within 2 years \([S+]\). While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; \([R+], [S+], [D+]\); and no data source, \([R-], [D-], [S-]\), challenges the estimate.
- There are no directly supporting data; or data from at least one source; \([R-], [D-], [S-]\) challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

- **2022**: Estimate based on extrapolation from data reported by national government. Reported data excluded because 102 percent greater than 100 percent. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. Programme reports three months vaccine stockout at national and subnational levels. GoC=R+ D+  
- **2021**: Estimate informed by reported data. Programme reports a two months vaccine stockout at the national and subnational levels. GoC=R+ D+  
- **2020**: Estimate informed by reported data. GoC=R+ D+  
- **2019**: Estimate informed by reported data. Programme reports a six month shortage of AD syringes. Programme reports three months vaccine stockout. GoC=R+ D+  
- **2018**: Estimate informed by reported data. GoC=R+ D+  
- **2017**: Estimate informed by reported data. GoC=R+ D+  
- **2016**: Estimate informed by reported data. GoC=R+ D+  
- **2015**: Estimate informed by reported data. GoC=R+ D+  
- **2014**: Estimate informed by reported data. GoC=R+ D+  
- **2013**: Estimate informed by reported data. GoC=R+ D+  
- **2012**: Estimate informed by reported data. GoC=R+ D+  
- **2011**: Estimate informed by interpolation between reported data. Reported data excluded because 101 percent greater than 100 percent. GoC=R+ S+ D+

### 2022: Estimate based on extrapolation from data reported by national government. Reported data excluded because 102 percent greater than 100 percent. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. Programme reports three months vaccine stockout at national and subnational levels. GoC=R+ D+

### 2021: Estimate informed by reported data. Programme reports a two months vaccine stockout at the national and subnational levels. GoC=R+ D+

### 2020: Estimate informed by reported data. GoC=R+ D+

### 2019: Estimate informed by reported data. Programme reports a six month shortage of AD syringes. Programme reports three months vaccine stockout. GoC=R+ D+

### 2018: Estimate informed by reported data. GoC=R+ D+

### 2017: Estimate informed by reported data. GoC=R+ D+

### 2016: Estimate informed by reported data. GoC=R+ D+

### 2015: Estimate informed by reported data. GoC=R+ D+

### 2014: Estimate informed by reported data. GoC=R+ D+

### 2013: Estimate informed by reported data. GoC=R+ D+

### 2012: Estimate informed by reported data. GoC=R+ D+

### 2011: Estimate informed by interpolation between reported data. Reported data excluded because 101 percent greater than 100 percent. GoC=R+ S+ D+

---

July 1, 2023; page 3

WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2024  
Data received as of June 26, 2023
Description:

2022: DTP1 coverage estimated based on DTP3 coverage of 98. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. Estimate challenged by: R-

2021: Estimate informed by reported data. GoC=R+ D+

2020: Consistency with trend in numerator. Estimate challenged by: R-

2019: Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+

2018: DTP1 coverage estimated based on DTP3 coverage of 97. Programme reports four months vaccine stockout. Estimate challenged by: R-

2017: Estimate informed by reported data. GoC=R+ D+

2016: DTP1 coverage estimated based on DTP3 coverage of 99. Estimate challenged by: R-

2015: DTP1 coverage estimated based on DTP3 coverage of 91. Estimate challenged by: D-R-

2014: DTP1 coverage estimated based on DTP3 coverage of 92. Estimate challenged by: R-

2013: DTP1 coverage estimated based on DTP3 coverage of 93. Official government estimate includes trivalent DTP coverage and does not include DTP doses administered as DTP-HepB-Hib pentavalent vaccine. Estimate challenged by: R-

2012: DTP1 coverage estimated based on DTP3 coverage of 96. Estimate challenged by: R-

2011: Estimate informed by reported data. GoC=R+ S+ D+
The WHO and UNICEF estimates of national immunization coverage (vaccine) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- **Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.**

- **Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.**

- **There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.**

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

- **2022:** Estimate informed by reported data. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. GoC=R+ D+  
- **2021:** Estimate informed by reported data. GoC=R+ D+  
- **2020:** Estimate informed by reported data. GoC=R+ D+  
- **2019:** Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+  
- **2018:** Estimate informed by reported data. Programme reports four months vaccine stockout. GoC=R+ D+  
- **2017:** Estimate informed by reported data. GoC=R+ D+  
- **2016:** Estimate informed by reported data. GoC=R+ D+  
- **2015:** Estimate informed by reported data. GoC=R+ D+  
- **2014:** Estimate informed by reported data. GoC=R+ D+  
- **2013:** Estimate informed by reported administrative data. Official government estimate includes trivalent DTP coverage and does not include DTP doses administered as DTP-HepB-Hib pentavalent vaccine. GoC=R+ D+  
- **2012:** Estimate informed by reported data. GoC=R+ D+  
- **2011:** Estimate informed by reported data. GoC=R+ S+ D+

---

The graph shows the trends in national immunization coverage for DTP3 in Jamaica from 2011 to 2022. The graph includes data from various sources such as WHO-UNICEF estimates, official government estimates, and administrative coverage. The quality of the estimates is indicated by the GoC scale, which includes support from reported data, surveys, and administrative data. The table below summarizes the coverage data and GoC for each year:

<table>
<thead>
<tr>
<th>Year</th>
<th>Estimate</th>
<th>Official</th>
<th>Administrative</th>
<th>Survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2021</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2020</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2019</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2018</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2017</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2016</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2015</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2014</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2013</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2012</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
<tr>
<td>2011</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>R+ S+ D+</td>
<td>NA NA</td>
</tr>
</tbody>
</table>
The WHO and UNICEF estimates of national immunization coverage (vuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

**2022:** Estimate informed by reported data. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. GoC=R+ D+

**2021:** Estimate informed by reported data. Programme reports a two months OPV vaccine stockout at the national and subnational levels. GoC=R+ D+

**2020:** Estimate informed by reported data. GoC=R+ D+

**2019:** Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+

**2018:** Estimate informed by reported data. Programme reports one month vaccine stockout. GoC=R+ D+

**2017:** Estimate informed by reported data. Programme reports vaccine stockout for 0.5 month. GoC=R+ D+

**2016:** Estimate informed by reported data. GoC=R+ D+

**2015:** Estimate informed by reported data. GoC=R+ D+

**2014:** Estimate informed by reported data. GoC=R+ D+

**2013:** Estimate informed by reported administrative data. Decline in reported administrative coverage is most likely due to national stockout for 1.5 months. Reported decline in government official estimate most likely a reporting error. GoC=R+ D+

**2012:** Estimate informed by reported data. GoC=R+ D+

**2011:** Estimate informed by reported data. GoC=R+ S+ D+

---

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO-UNICEF estimate</td>
<td>93</td>
<td>96</td>
<td>86</td>
<td>93</td>
<td>91</td>
<td>99</td>
<td>93</td>
<td>98</td>
<td>96</td>
<td>95</td>
<td>90</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Estimate type</td>
<td>R+ S+ D+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Official</td>
<td>93</td>
<td>96</td>
<td>86</td>
<td>93</td>
<td>91</td>
<td>99</td>
<td>93</td>
<td>98</td>
<td>96</td>
<td>95</td>
<td>90</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Administrative</td>
<td>93</td>
<td>96</td>
<td>86</td>
<td>93</td>
<td>91</td>
<td>99</td>
<td>93</td>
<td>98</td>
<td>96</td>
<td>95</td>
<td>90</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Survey</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data \([R+]\), coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division \([D+]\), and at least one supporting survey within 2 years \([S+]\). While well supported, the estimate still carries a risk of being wrong.

- Estimate is supported by at least one data source; \([R+]\), \([S+]\), or \([D+]\); and no data source, \([R-]\), \([D-]\), or \([S-]\), challenges the estimate.

- There are no directly supporting data; or data from at least one source; \([R-]\), \([D-]\), \([S-]\); challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative’s Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV).

**2022:** Estimate informed by reported data. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. Programme reports two months vaccine stockout at national level. GoC=R+ D+

**2021:** Estimate informed by reported data. GoC=R+ D+

**2020:** Estimate informed by reported data. GoC=R+ D+

**2019:** Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+

**2018:** Estimate informed by reported data. GoC=R+ D+

**2017:** Estimate informed by reported data. GoC=R+ D+

**2016:** Estimate informed by reported data. National rollout of IPV. GoC=R+ D+

**2015:** Estimate informed by reported data. Inactivated polio vaccine in September 2015. GoC=R+ D+

### Table:

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimate</strong></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>33</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td>92</td>
<td>94</td>
</tr>
<tr>
<td><strong>Estimate</strong></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td><strong>Official</strong></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>33</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td>95</td>
<td>92</td>
</tr>
<tr>
<td><strong>Administrative</strong></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Survey</strong></td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

**July 1, 2023; page 7** WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2024 data received as of June 26, 2023
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/uncertainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- **Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.**

- **Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.

- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

2022: Estimate informed by reported data. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. Programme reports four months vaccine stockout at national level. GoC=R+ D+

2021: Estimate informed by reported data. GoC=R+ D+

2020: Estimate informed by reported data. GoC=R+ D+

2019: Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+

2018: Estimate informed by reported data. Programme reports one month vaccine stockout at national level. GoC=R+ D+

2017: Estimate informed by reported data. GoC=R+ D+

2016: Estimate informed by reported data. Programme report vaccine stockouts at district level. GoC=R+ D+

2015: Estimate informed by reported data. GoC=R+ D+

2014: Estimate informed by reported data. GoC=R+ D+

2013: Estimate informed by reported data. GoC=R+ D+

2012: Estimate informed by reported data. GoC=R+ D+

2011: Estimate informed by reported data. GoC=R+ S+ D+
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Coverage estimates for the second dose of measles containing vaccine are for children by the nationally recommended age.

#### 2022:
- Estimate informed by reported data. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. Programme reports four months of vaccine stockout at national level. GoC=R+ D+

#### 2021:
- Estimate informed by reported data. GoC=R+ D+

#### 2020:
- Estimate informed by reported data. GoC=R+ D+

#### 2019:
- Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+

#### 2018:
- Estimate informed by reported data. Programme reports one month vaccine stockout at national level. GoC=R+ D+

#### 2017:
- Estimate informed by reported data. GoC=R+ D+

#### 2016:
- Estimate informed by reported data. Programme report vaccine stockouts at district level. GoC=R+ D+

#### 2015:
- Estimate informed by reported data. Increase in coverage due in part to change in recommended age from 4-6 years to 18 months of age. GoC=R+ D+

#### 2014:
- Estimate informed by reported data. Estimate challenged by: D-

#### 2013:
- Estimate informed by reported data. Estimate challenged by: D-

#### 2012:
- Estimate informed by reported data. Estimate challenged by: D-

#### 2011:
- Estimate informed by reported data. GoC=R+ D+

---

**Description:**

Coverage estimates for the second dose of measles containing vaccine are for children by the nationally recommended age.

- Estimate informed by reported data. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. Programme reports four months of vaccine stockout at national level. GoC=R+ D+
- Estimate informed by reported data. GoC=R+ D+
- Estimate informed by reported data. GoC=R+ D+
- Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+
- Estimate informed by reported data. Programme reports one month vaccine stockout at national level. GoC=R+ D+
- Estimate informed by reported data. GoC=R+ D+
- Estimate informed by reported data. Programme report vaccine stockouts at district level. GoC=R+ D+
- Estimate informed by reported data. Increase in coverage due in part to change in recommended age from 4-6 years to 18 months of age. GoC=R+ D+
- Estimate informed by reported data. Estimate challenged by: D-
- Estimate informed by reported data. Estimate challenged by: D-
- Estimate informed by reported data. Estimate challenged by: D-
- Estimate informed by reported data. GoC=R+ D+
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

For this revision, coverage estimates for the first dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine. Nationally reported coverage of rubella containing vaccine is not taken into consideration nor are they represented in the accompanying graph and data table.

2022: Estimate based on estimated MCV1. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. GoC=R+ D+

2021: Estimate based on estimated MCV1. GoC=R+ D+

2020: Estimate based on estimated MCV1. GoC=R+ D+

2019: Estimate based on estimated MCV1. Programme reports a six month shortage of AD syringes. GoC=R+ D+

2018: Estimate based on estimated MCV1. GoC=R+ D+

2017: Estimate based on estimated MCV1. GoC=R+ D+

2016: Estimate based on estimated MCV1. GoC=R+ D+

2015: Estimate based on estimated MCV1. GoC=R+ D+

2014: Estimate based on estimated MCV1. GoC=R+ D+

2013: Estimate based on estimated MCV1. GoC=R+ D+

2012: Estimate based on estimated MCV1. GoC=R+ D+

2011: Estimate based on estimated MCV1. GoC=R+ S+ D+
The WHO and UNICEF estimates of national immunization coverage (wunic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimate put</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Official</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Administrative</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Survey</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- **Estimate** is supported by reported data; [R+], [S+], [D+]; and no data source; [R-], [D-], [S-]; challenges the estimate.

- **Estimate** is supported by at least one data source; [R+], [S+], or [D+]; and no data source; [R-], [D-], [S-]; challenges the estimate.

- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

### Description:

2022: Estimate informed by reported data. WHO and UNICEF are aware of a 2022 Multiple Indicator Cluster Survey and await the final results. GoC=R+ D+

2021: Estimate informed by reported data. GoC=R+ D+

2020: Estimate informed by reported data. GoC=R+ D+

2019: Estimate informed by reported data. Programme reports a six month shortage of AD syringes. GoC=R+ D+

2018: Estimate informed by reported data. GoC=R+ D+

2017: Estimate informed by reported data. GoC=R+ D+

2016: Estimate informed by reported data. GoC=R+ D+

2015: Estimate informed by reported data. GoC=R+ D+

2014: Estimate informed by reported data. GoC=R+ D+

2013: Estimate informed by reported data. GoC=R+ D+

2012: Estimate informed by reported data. GoC=R+ D+

2011: Estimate informed by reported data. GoC=R+ S+ D+
Jamaica - Hib3

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- **Estimate is supported by reported data [R+]**, coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- **Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.**
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

<table>
<thead>
<tr>
<th>Year</th>
<th>Estimate</th>
<th>GoC</th>
<th>D+</th>
<th>S+</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2021</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2020</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2019</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2018</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2017</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2016</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2015</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2014</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2013</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2012</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
<tr>
<td>2011</td>
<td>96</td>
<td>R+</td>
<td>D+</td>
<td>S+</td>
</tr>
</tbody>
</table>

July 1, 2023; page 13

WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2024
data received as of June 26, 2023
The WHO and UNICEF estimates of national immunization coverage (vwnic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.
The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.
NOTE: A survey to measure vaccination coverage for infants (i.e., children aged 0 to 11 months) will sample children aged 12 to 23 months at the time of survey to capture the youngest annual cohort of children who should have completed the vaccination schedule. Because WUENIC are for infant vaccinations, survey data in this report are presented to reflect the birth year of the youngest survey cohort. For example, results for a survey conducted during December 2020 among children aged 12 to 23 months at the time of the survey reflect the immunization experience of children born in 2019. Depending on the timing of survey field work, results may reflect the immunization experience of children born and vaccinated 1 or 2 years prior to the survey field work.

### 2009 Jamaica Multiple Indicator Survey 2011

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Confirmation method</th>
<th>Coverage</th>
<th>Age cohort</th>
<th>Sample</th>
<th>Cards seen</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>C or H &lt;12 months</td>
<td>99.5</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>BCG</td>
<td>Card</td>
<td>77.8</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>BCG</td>
<td>Card or History</td>
<td>99.5</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>BCG</td>
<td>History</td>
<td>21.7</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>DTP1</td>
<td>C or H &lt;12 months</td>
<td>96.8</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card</td>
<td>77.8</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card or History</td>
<td>97.7</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>DTP1</td>
<td>History</td>
<td>19.9</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>DTP3</td>
<td>C or H &lt;12 months</td>
<td>89.9</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>DTP3</td>
<td>Card</td>
<td>77.8</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>DTP3</td>
<td>Card or History</td>
<td>91.5</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>DTP3</td>
<td>History</td>
<td>13.7</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>HepB1</td>
<td>C or H &lt;12 months</td>
<td>96.8</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card</td>
<td>77.8</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>HepB1</td>
<td>Card or History</td>
<td>97.7</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>HepB1</td>
<td>History</td>
<td>19.9</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>HepB3</td>
<td>C or H &lt;12 months</td>
<td>89.9</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card</td>
<td>77.8</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>HepB3</td>
<td>Card or History</td>
<td>91.5</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>HepB3</td>
<td>History</td>
<td>13.7</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>Hib1</td>
<td>C or H &lt;12 months</td>
<td>96.8</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>Hib1</td>
<td>Card</td>
<td>77.8</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
<tr>
<td>Hib1</td>
<td>Card or History</td>
<td>97.7</td>
<td>18-29 m</td>
<td>320</td>
<td>78</td>
</tr>
<tr>
<td>Hib1</td>
<td>History</td>
<td>19.9</td>
<td>18-29 m</td>
<td>-</td>
<td>78</td>
</tr>
</tbody>
</table>

### 2006 Jamaica Survey of Living Conditions 2008

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Confirmation method</th>
<th>Coverage</th>
<th>Age cohort</th>
<th>Sample</th>
<th>Cards seen</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>NA</td>
<td>99</td>
<td>6-59 m</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DTP3</td>
<td>NA</td>
<td>91.8</td>
<td>6-59 m</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HepB3</td>
<td>NA</td>
<td>58.1</td>
<td>6-59 m</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hib3</td>
<td>NA</td>
<td>65.5</td>
<td>6-59 m</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MCV1</td>
<td>NA</td>
<td>85.6</td>
<td>6-59 m</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pol3</td>
<td>NA</td>
<td>91.5</td>
<td>6-59 m</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

### 2004 Jamaica Multiple Indicator Cluster Survey 2005

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Confirmation method</th>
<th>Coverage</th>
<th>Age cohort</th>
<th>Sample</th>
<th>Cards seen</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>C or H &lt;12 months</td>
<td>94.3</td>
<td>18-29 m</td>
<td>298</td>
<td>74</td>
</tr>
<tr>
<td>BCG</td>
<td>Card</td>
<td>74</td>
<td>18-29 m</td>
<td>298</td>
<td>74</td>
</tr>
<tr>
<td>BCG</td>
<td>Card or History</td>
<td>96.1</td>
<td>18-29 m</td>
<td>298</td>
<td>74</td>
</tr>
<tr>
<td>BCG</td>
<td>History</td>
<td>22.1</td>
<td>18-29 m</td>
<td>298</td>
<td>74</td>
</tr>
<tr>
<td>DTP1</td>
<td>C or H &lt;12 months</td>
<td>91.4</td>
<td>18-29 m</td>
<td>298</td>
<td>74</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card</td>
<td>74.5</td>
<td>18-29 m</td>
<td>298</td>
<td>74</td>
</tr>
<tr>
<td>DTP1</td>
<td>Card or History</td>
<td>96.1</td>
<td>18-29 m</td>
<td>298</td>
<td>74</td>
</tr>
</tbody>
</table>
Jamaica - survey details

DTP1 History 21.6 18-29 m 298 74
DTP3 C or H <12 months 81.5 18-29 m 298 74
DTP3 Card 72.9 18-29 m 298 74
DTP3 Card or History 86.9 18-29 m 298 74
DTP3 History 14 18-29 m 298 74
MCV1 C or H <12 months 86.8 18-29 m 298 74
MCV1 Card 70 18-29 m 298 74
MCV1 Card or History 91.1 18-29 m 298 74
MCV1 History 21.1 18-29 m 298 74
Pol1 C or H <12 months 95.7 18-29 m 298 74
Pol1 Card 74.4 18-29 m 298 74
Pol1 Card or History 95.9 18-29 m 298 74
Pol1 History 21.5 18-29 m 298 74
Pol3 C or H <12 months 80.1 18-29 m 298 74
Pol3 Card 73 18-29 m 298 74
Pol3 Card or History 86.2 18-29 m 298 74
Pol3 History 13.2 18-29 m 298 74

2004 Survey of Childhood Vaccine Coverage in the Parishes of Jamaica

Vaccine Confirmation method Coverage Age cohort Sample Cards seen
BCG Card or History 98.9 12-23 m 3744 100
DTP3 Card or History 97.9 12-23 m 3744 100
HepB3 Card or History 97.9 12-23 m 3744 100
Hib3 Card or History 97.9 12-23 m 3744 100
MCV1 Card or History 93.7 12-23 m 3744 100
Pol3 Card or History 97.1 12-23 m 3744 100
Further information and estimates for previous years are available at:
https://data.unicef.org/topic/child-health/immunization/
https://immunizationdata.who.int/listing.html